Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02478788 · ClinicalTrials.gov registry record · Phase 4
Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
NCT02478788 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 153 participants.
The verdict
NCT02478788, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
Study Summary
The main purpose of this study is to see the affects of the study medication called mixed amphetamine salts-extended release (MAS-XR) on brain function by taking brain pictures. The researchers also want to see if MAS-XR makes your child more or less likely to develop problems like acting out (i.e. periods of irritability, agitation, aggression). MAS-XR is approved by the United States Food and Drug Administration (FDA) to treat attention deficit hyperactivity disorder (ADHD) in adults, children and adolescents.
Interventions
- DRUG Placebo
- DRUG mixed amphetamine salts-extended release (MAS-XR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2015-11 |
| Est. Completion | 2022-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02478788
The ClinicalTrials.gov registry entry for NCT02478788 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02478788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02478788 about?
NCT02478788 is a clinical study titled "Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder". The main purpose of this study is to see the affects of the study medication called mixed amphetamine salts-extended release (MAS-XR) on brain function by taking brain pictures. The researchers also want to see if MAS-XR makes your child more or less likely to develop problems like acting out (i.e. ...
What is the current status of trial NCT02478788?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 2015-11. Estimated completion is 2022-12.
What interventions are being tested in trial NCT02478788?
The interventions under investigation include: Placebo (DRUG), mixed amphetamine salts-extended release (MAS-XR) (DRUG).
Who is sponsoring clinical trial NCT02478788?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.